Business Context and Reporting Period
Company: NANOVIRICIDES, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: February 26, 2013
Event: Entry into and termination of material definitive agreements regarding Series C Convertible Preferred Stock.
Key Financial Metrics
This filing does not report standard operating metrics such as revenue, profit, cash flow, or margins. The primary financial data relates to a specific capital transaction:
- Shares Retired: 1,825.744 shares of Series C Convertible Preferred Stock.
- Total Redemption Price: $2,014,921.41.
- Accrued Dividends Included: $6,002.45.
- Premium Applied: 10%.
Material Changes
On February 26, 2013, the Company entered into a letter agreement with Seaside 88, LP to retire the remaining unconverted Series C Preferred Stock purchased on December 21, 2012. Concurrently, the Company terminated the Securities Purchase Agreement dated June 26, 2012. Both parties agreed to release each other from any liability connected to the Purchase Agreement or the Series C Preferred Stock.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the resolution of the prior investment agreement. The transaction effectively closes the liability associated with the Series C Preferred Stock issuance.
Investor Verification Checklist
- Verify the cash outflow of approximately $2.01 million for the stock redemption.
- Confirm the removal of 1,825.744 Series C Preferred shares from the capital structure.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale.
- Ensure the release of liability from the June 26, 2012 Purchase Agreement is legally finalized.